Lytix Biopharma
Manufacturing · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sandakerveien 138, Oslo, Oslo, 0484, Nor...Phone Number
+47 77675500Website
www.lytixbiopharma.comRevenue
<$5 MillionStock Symbol
6BG.FIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lytix Biopharma
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lytix Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lytix Biopharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Lytix Biopharma
Funding: Get notified immidiatlly once Lytix Biopharma has new funding data
Lytix Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Lytix Biopharma is spiking on competitors!
Click to see if Lytix Biopharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Lytix Biopharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Lytix Biopharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Lytix Biopharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Lytix Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lytix Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lytix Biopharma.
Lytix Biopharma financials insights
Gather financial insights about Lytix Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Unspecified
$10.4M
2025
Other Financing Round
$9.8M
Lytix Biopharma Tech Stack
A closer look at the technologies used by Lytix Biopharma
See more technologies
Most Recent Scoops
Project
Lytix Biopharma has reported that its completed ATLAS-IT-05 study of ruxotemitide in combination with pembrolizumab demonstrated intratumoral cancer cell killing, complete regression of treated melanoma lesions, and abscopal regression of uninjected distant lesions, with durable responses observed beyond 24 months in some patients and a manageable safety profile consistent with local immunotherapy and pembrolizumab.
Medical Research, Pharmaceuticals
Project
Lytix Biopharma has announced that its second oncology asset, LTX-401, a small molecule platform candidate intended for deep-seated tumors, is currently in late-stage preclinical development, with clinical entry planned for 2027.
Product Development, Medical Research, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Executive Move
Board of Directors
Lytix Biopharma News & Media
Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion
Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42 million underwritten public offering. The offering is expected to close on November 22, 2024, and the gross proceeds from the offering are expected to be approximately USD 42.0 million. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares. TheLytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization
Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its third quarter 2024 results. Lytix achieved substantial progress in its clinical pipeline, progressing towards commercialization. “Our progress this quarter underscores Lytix’s potential to deliver transformative treatments for cancer patients,” said Øystein Rekdal, CEO of Lytix Biopharma. “The positive dataLytix Biopharma: Invitation to Q3 2024 Results Presentation
Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its third quarter 2024 financial results on Tuesday, 19 November 2024. Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights. Date: Tuesday, 19 November 2024 Time: 10:30 AM CET Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com,First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Oslo, Norway, November 6, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lytix Biopharma
Sign Up For FreeTo access detailed company insights
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.... Read More
